Home > Publications Database > Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. > print

001     265939
005     20240808170117.0
024 7 _ |a 10.1016/j.cell.2023.10.001
|2 doi
024 7 _ |a pmid:37918394
|2 pmid
024 7 _ |a 0092-8674
|2 ISSN
024 7 _ |a 1097-4172
|2 ISSN
024 7 _ |a altmetric:155960108
|2 altmetric
037 _ _ |a DZNE-2023-01062
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Reincke, Momsen
|0 P:(DE-2719)2812526
|b 0
|e First author
|u dzne
245 _ _ |a Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.
260 _ _ |a New York, NY
|c 2023
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1700487725_2203
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to intracellular 4-1BB/CD3ζ domains. NMDAR-CAAR T cells recognize a large panel of human patient-derived autoantibodies, release effector molecules, proliferate, and selectively kill antigen-specific target cell lines even in the presence of high autoantibody concentrations. In a passive transfer mouse model, NMDAR-CAAR T cells led to depletion of an anti-NMDAR B cell line and sustained reduction of autoantibody levels without notable off-target toxicity. Treatment of patients may reduce side effects, prevent relapses, and improve long-term prognosis. Our preclinical work paves the way for CAAR T cell phase I/II trials in NMDAR encephalitis and further autoantibody-mediated diseases.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Autoantibodies: metabolism
|2 MeSH
650 _ 2 |a Encephalitis: metabolism
|2 MeSH
650 _ 2 |a Encephalitis: therapy
|2 MeSH
650 _ 2 |a Receptors, N-Methyl-D-Aspartate
|2 MeSH
650 _ 2 |a T-Lymphocytes
|2 MeSH
650 _ 2 |a Autoimmune Diseases
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 7 |a CAAR T cell
|2 Other
650 _ 7 |a CAAR T cell
|2 Other
650 _ 7 |a CAAR T cell
|2 Other
650 _ 7 |a CAAR T cell
|2 Other
650 _ 7 |a CAAR T cell
|2 Other
650 _ 7 |a CAAR T cell
|2 Other
650 _ 7 |a NMDA receptor encephalitis
|2 Other
650 _ 7 |a T cells
|2 Other
650 _ 7 |a autoimmune encephalitis
|2 Other
650 _ 7 |a autoimmunity
|2 Other
650 _ 7 |a cell therapy
|2 Other
650 _ 7 |a chimeric autoantibody receptor
|2 Other
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 7 |a Receptors, N-Methyl-D-Aspartate
|2 NLM Chemicals
693 _ _ |0 EXP:(DE-2719)LAT-20190308
|5 EXP:(DE-2719)LAT-20190308
|e Laboratory Automation Technologies (CRFS-LAT) / Bonn
|x 0
700 1 _ |a von-Wardenburg, Niels-Oliver
|0 P:(DE-2719)9000805
|b 1
|u dzne
700 1 _ |a Homeyer, Marie Alice
|0 P:(DE-2719)9001962
|b 2
700 1 _ |a Kornau, Hans-Christian
|0 P:(DE-2719)2811900
|b 3
|u dzne
700 1 _ |a Spagni, Gregorio
|0 P:(DE-2719)9002395
|b 4
|u dzne
700 1 _ |a Li, Lucie Y
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Kreye, Jakob
|0 P:(DE-2719)2811468
|b 6
|u dzne
700 1 _ |a Sánchez-Sendín, Elisa
|0 P:(DE-2719)2812653
|b 7
|u dzne
700 1 _ |a Blumenau, Sonja
|0 P:(DE-2719)9002227
|b 8
|u dzne
700 1 _ |a Stappert, Dominik
|0 P:(DE-2719)2812160
|b 9
|u dzne
700 1 _ |a Radbruch, Helena
|b 10
700 1 _ |a Hauser, Anja E
|b 11
700 1 _ |a Künkele, Annette
|b 12
700 1 _ |a Edes, Inan
|b 13
700 1 _ |a Schmitz, Dietmar
|0 P:(DE-2719)2810725
|b 14
|u dzne
700 1 _ |a Prüss, Harald
|0 P:(DE-2719)2810931
|b 15
|e Last author
|u dzne
773 _ _ |a 10.1016/j.cell.2023.10.001
|g Vol. 186, no. 23, p. 5084 - 5097.e18
|0 PERI:(DE-600)2001951-8
|n 23
|p 5084 - 5097.e18
|t Cell
|v 186
|y 2023
|x 0092-8674
856 4 _ |u https://pub.dzne.de/record/265939/files/DZNE-2023-01062.pdf
856 4 _ |u https://pub.dzne.de/record/265939/files/DZNE-2023-01062.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:265939
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812526
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000805
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001962
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811900
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9002395
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811468
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812653
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)9002227
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812160
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810725
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2810931
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 1
914 1 _ |y 2023
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a IF >= 60
|0 StatID:(DE-HGF)9960
|2 StatID
|b CELL : 2022
|d 2023-10-22
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
920 1 _ |0 I:(DE-2719)1040190
|k LAT
|l Laboratory Automation Technologies (CRFS-LAT)
|x 1
920 1 _ |0 I:(DE-2719)1810004
|k AG Schmitz
|l Network Dysfunction
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1810003
980 _ _ |a I:(DE-2719)1040190
980 _ _ |a I:(DE-2719)1810004
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21